

D3
Amended

[~~4-[3-(difluoromethyl)-5-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-1-yl]benzenesulfonamide;~~]

4-[5-(3-fluoro-4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide;
4-[4-chloro-5-phenyl-1H-pyrazol-1-yl]benzenesulfonamide;
4-[5-(4-chlorophenyl)-3-(hydroxymethyl)-1H-pyrazol-1-yl]benzenesulfonamide; and
4-[5-(4-(N,N-dimethylamino)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide.

REMARKS

Claims 16-20 and 23-36 were previously allowed and the issue fee was paid. The Claims have been amended to remove the subject matter allowed in US Patent No. 5,521,207, and as such do not require any additional search or examination. The amendment does not involve materially added work on the part of the Office.

The Claims were recently compared with those of the '207 patent and the error was identified.

It is respectfully submitted that this case is in condition for issuance. Accordingly, issuance of Claims 16-20, 23-27, and 29-36 are respectfully requested.

Respectfully submitted,

Joe Bullock

Joseph W. Bullock
Attorney for Applicants
Registration No. 37,103
Tel: (314) 694-9094

G.D. Searle & Co.
Corporate Patent Office
P.O. Box 5110
Chicago, IL 60680-9889